41,544 Shares in Electromed, Inc. $ELMD Bought by Isthmus Partners LLC

Isthmus Partners LLC bought a new position in Electromed, Inc. (NYSE:ELMD) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 41,544 shares of the company’s stock, valued at approximately $1,173,000. Isthmus Partners LLC owned about 0.50% of Electromed as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in ELMD. Legal & General Group Plc acquired a new position in Electromed during the second quarter valued at approximately $82,000. SG Americas Securities LLC lifted its stake in shares of Electromed by 51.5% in the first quarter. SG Americas Securities LLC now owns 5,905 shares of the company’s stock worth $138,000 after buying an additional 2,007 shares during the last quarter. IFP Advisors Inc lifted its stake in shares of Electromed by 101.0% in the second quarter. IFP Advisors Inc now owns 4,023 shares of the company’s stock worth $170,000 after buying an additional 2,022 shares during the last quarter. Gabelli Funds LLC lifted its stake in shares of Electromed by 10.9% in the first quarter. Gabelli Funds LLC now owns 40,700 shares of the company’s stock worth $953,000 after buying an additional 4,000 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Electromed by 49.3% during the 1st quarter. Bank of America Corp DE now owns 17,059 shares of the company’s stock worth $399,000 after buying an additional 5,634 shares during the period. Institutional investors own 40.82% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Morgan Stanley set a $50.00 target price on shares of Electromed in a research note on Wednesday, August 26th. Zacks Research lowered shares of Electromed from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Finally, Lake Street Capital boosted their target price on shares of Electromed from $36.00 to $47.00 and gave the stock a “buy” rating in a research report on Wednesday, August 26th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, Electromed has a consensus rating of “Moderate Buy” and an average target price of $43.75.

Electromed Stock Down 1.6%

ELMD opened at $26.87 on Friday. The firm has a market capitalization of $222.67 million, a P/E ratio of 35.83 and a beta of 0.40. The stock’s 50 day moving average price is $29.77 and its two-hundred day moving average price is $33.89. Electromed, Inc. has a 12-month low of $23.01 and a 12-month high of $47.40.

Electromed Profile

Electromed, Inc is a medical device company that develops, manufactures and distributes airway clearance systems. Its products are designed to help loosen and mobilize pulmonary secretions, supporting airway clearance for patients with chronic respiratory conditions.

The company’s principal product is the SmartVest Airway Clearance System, an inflatable vest system that uses high-frequency chest wall oscillation (HFCWO) technology. SmartVest systems are used in the management of conditions such as bronchiectasis, cystic fibrosis, neuromuscular disorders and other diseases associated with impaired mucus clearance.